Hopkinton’s Spring Bank Pharmaceuticals continues to set its sights on completing the second phase of human trials for its hepatitis medicine as the company reported $4.3 million in losses in the second quarter on Thursday.
The company’s financials represented mounting losses, up from $2.3 million for the second quarter of 2015, as it continues to push its lead compound, SB 9200, through phase 2a clinical trials. Company President and CEO Martin Driscoll said with a strengthened balance sheet from the company’s $11.3-million initial public offering, the company plans to report data on the results in the first half of 2017.
At the end of the quarter, Spring Bank had $19.6 million in cash, cash equivalents and marketable securities.
